

DAFTAR PUSTAKA

- Anderson, J.L., Adams, C.D., Antman, E.M., Bridges, C.R., Califf, R.M., Casey, D.E., *et al.*, 2007. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. *Journal of the American College of Cardiology*, **50**: e1–e157.
- Anderson, J.L., Adams, C.D., Antman, E.M., Bridges, C.R., Califf, R.M., Casey, D.E., *et al.*, 2013. 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*, **61**: e179–e347.
- Anonymus, 2005. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. *The Lancet*, **366**: 1622–1632.
- Antiplatelet Trialists' Collaboration, 1994. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. *BMJ: British Medical Journal*, **308**: 81–106.
- Antman, E., Bassand, J.P., Klein, W., Ohman, M., Lopez Sendon, J.L., Rydén, L., *et al.*, 2000. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction: The Joint European Society of Cardiology/ American College of Cardiology Committee. *Journal of the American College of Cardiology*, **36**: 959–969.
- Antman, E.M., Morrow, D.A., McCabe, C.H., Murphy, S.A., Ruda, M., Sadowski, Z., *et al.*, 2006. Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. *New England Journal of Medicine*, **354**: 1477–1488.

- Apple, F.S., Jesse, R.L., Newby, L.K., Wu, A.H.B., and Christenson, R.H., 2007. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biochemical Markers of Acute Coronary Syndromes. *Circulation*, **115**: e352–e355.
- Awtry, E.H. and Loscalzo, J., 2000. Aspirin. *Circulation*, **101**: 1206–1218.
- Badano, L., Cassin, M., Solinas, L., Burelli, C., Macor, F., and Zanuttini, D., 1999. Clinical impact of local implementation of agreed guidelines for the management of patients with acute myocardial infarction. *Giornale Italiano Di Cardiologia*, **29**: 39–47.
- Baigent, C., Collins, R., Appleby, P., Parish, S., Sleight, P., and Peto, R., 1998. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. *BMJ*, **316**: 1337–1343.
- Baigent, C., Sudlow, C., Collins, R., and Peto, R., 2002. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*, **324**: 71–86.
- Bangalore, S., Messerli, F.H., Fang-Shu, O., Tamis-Holland, J., Palazzo, A., Roe, M.T., *et al.*, 2010. The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. *European Heart Journal*, **31**: 552–560.
- Barker, P.H. and Clanachan, A.S., 1982. Inhibition of adenosine accumulation into guinea pig ventricle by benzodiazepines. *European Journal of Pharmacology*, **78**: 241–244.
- Bersot, T.P., 2011. Drug Therapy for Hypercholesterolemia and Dyslipidemia, dalam: Brunton, L., Chabner, B., Knollman, B. (Eds.), *Goodman and Gilman's The Pharmacological Basis of Therapeutics, Twelfth Edition*. McGraw Hill Professional, pp. 895.
- Berwanger, O., Guimarães, H.P., Laranjeira, L.N., Cavalcanti, A.B., Kodama, A.A., Zazula, A.D., *et al.*, 2012. Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: the BRIDGE-ACS randomized trial. *JAMA*, **307**: 2041–2049.
- Braunwald, E., 1998. Unstable Angina An Etiologic Approach to Management. *Circulation*, **98**: 2219–2222.

- Braunwald, E., Mark, D.B., and Jones, R.H., 1994^a. Unstable angina: diagnosis and management. Guideline overview. Agency for Health Care Policy and Research. *Journal of the National Medical Association*, **86**: 649–712.
- Braunwald, E., McCabe, C.H., Cannon, C.P., and Muller, J.E., 1994^b. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. *Circulation*, **89**: 1545–1556.
- Campbell, C.L., Smyth, S., Montalescot, G., and Steinhubl, S.R., 2007. Aspirin dose for the prevention of cardiovascular disease: a systematic review. *JAMA*, **297**: 2018–2024.
- Chandra, N.C., Ziegelstein, R.C., Rogers, W.J., Tiefenbrunn, A.J., Gore, J.M., French, W.J., *et al.*, 1998. Observations of the treatment of women in the United States with myocardial infarction: a report from the National Registry of Myocardial Infarction-I. *Archives of Internal Medicine*, **158**: 981–988.
- Chen, Z.M., Jiang, L.X., Chen, Y.P., Xie, J.X., Pan, H.C., Peto, R., *et al.*, 2005. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. *The Lancet*, **366**: 1607–1621.
- Crouch, M.A., Colucci, V.J., Howard, P.A., and Spinler, S.A., 2011. P2Y₁₂ receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome. *The Annals of Pharmacotherapy*, **45**: 1151–1156.
- CTT, 2010. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Cholesterol Treatment Trialists' Collaboration. *Lancet*, **376**: 1670–1681.
- Donahoe, S.M., Stewart, G.C., McCabe, C.H., Mohanavelu, S., Murphy, S.A., Cannon, C.P., *et al.*, 2007. Diabetes and mortality following acute coronary syndromes. *JAMA*, **298**: 765–775.
- Dooley, J., Chang, A.M., Salhi, R., and Hollander, J.E., 2013. Relationship Between Body Mass Index and Prognosis of Patients Presenting With Potential Acute Coronary Syndromes. *Academic emergency medicine: official journal of the Society for Academic Emergency Medicine*, **20**: 904–910.
- Eikelboom, J.W., Quinlan, D.J., Mehta, S.R., Turpie, A.G., Menown, I.B., and Yusuf, S., 2005. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. *Circulation*, **112**: 3855–3867.

- Falk, E., Shah, P.K., and Fuster, V., 1995. Coronary Plaque Disruption. *Circulation*, **92**: 657–671.
- Falkstedt, D., Hemmingsson, T., Rasmussen, F., and Lundberg, I., 2006. Body mass index in late adolescence and its association with coronary heart disease and stroke in middle age among Swedish men. *International Journal of Obesity*, **31**: 777–783.
- Franzosi, M.G., Santoro, E., Vita, C.D., Geraci, E., Lotto, A., Maggioni, A.P., *et al.*, 1998^a. Ten-Year Follow-Up of the First Megatrial Testing Thrombolytic Therapy in Patients With Acute Myocardial Infarction Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 Study. *Circulation*, **98**: 2659–2665.
- Franzosi, M.G., Santoro, E., Zuanetti, G., Baigent, C., Collins, R., Flather, M., *et al.*, 1998^b. Indications for ACE Inhibitors in the Early Treatment of Acute Myocardial Infarction Systematic Overview of Individual Data From 100 000 Patients in Randomized Trials. *Circulation*, **97**: 2202–2212.
- FTT, 1994. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. *Lancet*, **343**: 311–322.
- Fuster, V., Moreno, P.R., Fayad, Z.A., Corti, R., and Badimon, J.J., 2005. Atherothrombosis and High-Risk Plaque: Part I: Evolving Concepts. *Journal of the American College of Cardiology*, **46**: 937–954.
- GISSI, 1986. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). *Lancet*, **1**: 397–402.
- GISSI, 1994. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. *Lancet*, **343**: 1115–1122.
- Gonzalez, E.R. and Briggs, G.C., 2006. Acute Myocardial Infarction, dalam: Helms, R.A., Quan, D.J., Herfindal, E.T., Gourley, D.R. (Eds.), *Textbook of Therapeutics: Drug and Disease Management*. Lippincott Williams & Wilkins, Philadelphia, pp. 597–629.
- Grundy, S.M., Cleeman, J.I., Merz, C.N.B., Brewer, H.B., Clark, L.T., Hunnigake, D.B., *et al.*, 2004. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. *Circulation*, **110**: 227–239.

- Hoehn-Saric, R. and McLeod, D.R., 1987. Cardiac symptoms and anxiety disorders: contributing factors and pharmacologic treatment. *The American Journal of Cardiology*, **60**: 68J–73J.
- Huffman, M.D., Prabhakaran, D., Abraham, A.K., Krishnan, M.N., Nambiar, A.C., and Mohanan, P.P., 2013. Optimal In-Hospital and Discharge Medical Therapy in Acute Coronary Syndromes in Kerala Results From the Kerala Acute Coronary Syndrome Registry. *Circulation: Cardiovascular Quality and Outcomes*, **6**: 436–443.
- Hulten, E., Jackson, J.L., Douglas, K., George, S., and Villines, T.C., 2006. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. *Archives of Internal Medicine*, **166**: 1814–1821.
- ISIS, 1986. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. *Lancet*, **2**: 57–66.
- ISIS, 1988. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. *Lancet*, **2**: 349–360.
- ISIS, 1995. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. *Lancet*, **345**: 669–685.
- James, S.K., Roe, M.T., Cannon, C.P., Cornel, J.H., Horrow, J., Husted, S., *et al.*, 2011. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. *BMJ: British Medical Journal*, **342**: 1–11.
- Katristsis, D., Karvouni, E., and Webb-Peploe, M.M., 2003. Reperfusion in acute myocardial infarction: current concepts. *Progress in Cardiovascular Diseases*, **45**: 481–492.
- Kementerian Kesehatan, 2009. *Keputusan Menteri Kesehatan Republik Indonesia Nomor 854 Tahun 2009 Tentang Pedoman Pengendalian Penyakit Jantung dan Pembuluh Darah*. Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kowalak, J.P., Welsh, W., and Mayer, B., 2003. Sistem Kardiovaskuler, dalam: *Buku Ajar Patofisiologi* diterjemahkan dari bahasa Inggris oleh Hartono, A. Buku Kedokteran EGC, Jakarta, hal. 140–141.

- Kronmal, R.A., Cain, K.C., Ye, Z., and Omenn, G.S., 1993. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. *Archives of Internal Medicine*, **153**: 1065–1073.
- Kumar, A. and Cannon, C.P., 2009. Acute Coronary Syndromes: Diagnosis and Management, Part I. *Mayo Clinic Proceedings*, **84**: 917–938.
- Lameshow, S., Hosmer Jr, D.W., Klar, J., and Lwanga, S.K., 1990. *Adequacy of Sample Size in Health Studies*. John Wiley & Sons, Ltd, Chicester, pp. 36-37.
- Levine, G.N., Bates, E.R., Blankenship, J.C., Bailey, S.R., Bittl, J.A., Cercek, B., et al., 2011. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Circulation*, **124**: e574–e651.
- Lloyd-Jones, D., Adams, R., Carnethon, M., Simone, G.D., Ferguson, T.B., Flegal, K., et al., 2009. Heart Disease and Stroke Statistics—2009 Update A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*, **119**: e21–e181.
- Lüscher, T.F., Bax, J., Gersh, B.J., Hindricks, G., Landmesser, U., Ruschitzka, F., et al. (Eds.), 1985. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. *European Heart Journal*, **6**: 199–226.
- Madjid, M., Casscells, S.W., and Willerson, J.T., 2007. Atherosclerotic Vulnerable Plaques: Pathophysiology, Detection, and Treatment, dalam: Willerson, J.T., Wellens, H.J.J., Cohn, J.N., Holmes Jr., D.R. (Eds.), *Cardiovascular Medicine*. Springer London, London, pp. 621–639.
- Mahaffey, K.W., Wojdyla, D.M., Carroll, K., Becker, R.C., Storey, R.F., Angiolillo, D.J., et al., 2011. Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. *Circulation*, **124**: 544–554.
- Makkar, K.M., Sanoski, C.A., and Spinler, S.A., 2009. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. *Pharmacotherapy*, **29**: 31–48.
- Mark, D.B. and Newby, L.K., 2003. Early hospital discharge after uncomplicated myocardial infarction: are further improvements possible? *European Heart Journal*, **24**: 1613–1615.

- McDermott, M.M., Mandapat, A.L., Moates, A., Albay, M., Chiou, E., Celic, L., *et al.*, 2003. Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. *Archives of Internal Medicine*, **163**: 2157–2162.
- Mega, J.L., Close, S.L., Wiviott, S.D., Shen, L., Hockett, R.D., Brandt, J.T., *et al.*, 2009. Cytochrome P-450 Polymorphisms and Response to Clopidogrel. *New England Journal of Medicine*, **360**: 354–362.
- Mehta, S.R., Yusuf, S., Chrolavicius, S., Ajani, A.E., Avezum, A., Bassand, J.P., *et al.*, 2010. Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. *New England Journal of Medicine*, **363**: 930–942.
- Menon, V., Harrington, R.A., Hochman, J.S., Cannon, C.P., Goodman, S.D., Wilcox, R.G., *et al.*, 2004. Thrombolysis and adjunctive therapy in acute myocardial infarction: The seventh accp conference on antithrombotic and thrombolytic therapy. *Chest*, **126**: 549S–575S.
- Muchid, A., Umar, F., Chusun, Purnama, N.R., Istiqomah, S.N., Masrul, dkk., 2006. *Pharmaceutical Care untuk Pasien Penyakit Jantung Koroner: Fokus Sindrom Koroner Akut*. Direktorat Bina Farmasi Komunitas dan Klinik, Jakarta.
- Naghavi, M., Libby, P., Falk, E., Casscells, S.W., Litovsky, S., Rumberger, J., *et al.*, 2003. From Vulnerable Plaque to Vulnerable Patient A Call for New Definitions and Risk Assessment Strategies: Part I. *Circulation*, **108**: 1664–1672.
- Nakatani, D., Sakata, Y., Suna, S., Usami, M., Matsumoto, S., Shimizu, M., *et al.*, 2013. Incidence, Predictors, and Subsequent Mortality Risk of Recurrent Myocardial Infarction in Patients Following Discharge for Acute Myocardial Infarction. *Circulation Journal*, **77**: 439–446.
- Newby, L.K., Eisenstein, E.L., Califf, R.M., Thompson, T.D., Nelson, C.L., Peterson, E.D., *et al.*, 2000. Cost Effectiveness of Early Discharge after Uncomplicated Acute Myocardial Infarction. *New England Journal of Medicine*, **342**: 749–755.
- O’Gara, P.T., Kushner, F.G., Ascheim, D.D., Casey, D.E., Chung, M.K., Lemos, J.A. de, *et al.*, 2013. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*, **127**: 529–555.
- Odeberg, J., Freitag, M., Forssell, H., Vaara, I., Persson, M.-L., Odeberg, H., *et al.*, 2014. The influence of smoking and impaired glucose homeostasis on

the outcome in patients presenting with an acute coronary syndrome: a cross-sectional study. *BMJ Open*, **4**: 1–6.

Page, R.L. and Nappi, J.M., 2012. Acute Coronary Syndrome, dalam: Alldredge, B.K., Corelli, R.L., Ernst, M.E. (Eds.), *Koda-Kimble and Young's Applied Therapeutics: The Clinical Use of Drugs*. Lippincott Williams & Wilkins, Philadelphia, pp. 406–422.

Pernet, K., Ecarnot, F., Chopard, R., Seronde, M.-F., Plastaras, P., Schiele, F., *et al.*, 2014. Microvascular obstruction assessed by 3-tesla magnetic resonance imaging in acute myocardial infarction is correlated with plasma troponin I levels. *BMC Cardiovascular Disorders*, **14**: 1–8.

Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., *et al.*, 2003. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. *New England Journal of Medicine*, **348**: 1309–1321.

Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., *et al.*, 1999. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. *New England Journal of Medicine*, **341**: 709–717.

Polverejan, E., Gardiner, J.C., Bradley, C.J., Holmes-Rovner, M., and Rovner, D., 2003. Estimating mean hospital cost as a function of length of stay and patient characteristics. *Health Economics*, **12**: 935–947.

Pope, J.H., Ruthazer, R., Beshansky, J.R., Griffith, J.L., and Selker, H.P., 1998. Clinical Features of Emergency Department Patients Presenting with Symptoms Suggestive of Acute Cardiac Ischemia: A Multicenter Study. *Journal of Thrombosis and Thrombolysis*, **6**: 63–74.

Sabatine, M.S., Cannon, C.P., Gibson, C.M., López-Sendón, J.L., Montalescot, G., Theroux, P., *et al.*, 2005. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. *New England Journal of Medicine*, **352**: 1179–1189.

Saleh, S.S., Callan, M., Therriault, M., and Landor, N., 2010. The cost impact of hospital-acquired conditions among critical care patients. *Medical Care*, **48**: 518–526.

Shiraishi, J., Kohno, Y., Sawada, T., Ito, D., Kimura, M., Ariyoshi, M., *et al.*, 2011. Systolic blood pressure at admission, clinical manifestations, and in-hospital outcomes in patients with acute myocardial infarction. *Journal of Cardiology*, **58**: 54–60.

- Smith, S.C., Benjamin, E.J., Bonow, R.O., Braun, L.T., Creager, M.A., Franklin, B.A., *et al.*, 2011. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update A Guideline From the American Heart Association and American College of Cardiology Foundation. *Circulation*, **124**: 2458–2473.
- Soekhlal, R.R., Burgers, L.T., Redekop, W.K., and Tan, S.S., 2013. Treatment costs of acute myocardial infarction in the Netherlands. *Netherlands Heart Journal*, **21**: 230–235.
- Spinler, S.A. and Denus, S. de, 2013. Acute Coronary Syndromes, dalam: Chisholm-Burns, M., Schwinghammer, T., Wells, B., Malone, P., DiPiro, J. (Eds.), *Pharmacotherapy Principles and Practice, Third Edition*. McGraw Hill Professional, New York, pp. 139–168.
- Sulaiman, K., Prashanth, P., Al-Zakwani, I., Al-Mahmeed, W., Al-Motarreb, A., Al Suwaidi, J., *et al.*, 2012. Impact of Anemia on In-Hospital, One-Month and One-Year Mortality in Patients with Acute Coronary Syndrome from the Middle East. *Clinical Medicine & Research*, **10**: 65–71.
- Swedberg, K., Held, P., Kjekshus, J., Rasmussen, K., Rydén, L., and Wedel, H., 1992. Effects of the Early Administration of Enalapril on Mortality in Patients with Acute Myocardial Infarction. *New England Journal of Medicine*, **327**: 678–684.
- Topol, E., Califf, R., Ohman, E., Skene, A., Wilcox, R., Grinfeld, L., *et al.*, 1997. A Comparison of Reteplase with Alteplase for Acute Myocardial Infarction. *New England Journal of Medicine*, **337**: 1118–1123.
- Topol, E.J., Burek, K., O’Neill, W.W., Kewman, D.G., Kander, N.H., Shea, M.J., *et al.*, 1988. A Randomized Controlled Trial of Hospital Discharge Three Days after Myocardial Infarction in the Era of Reperfusion. *New England Journal of Medicine*, **318**: 1083–1088.
- Van de Werf, F., 1999. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. *The Lancet*, **354**: 716–722.
- Vasan, R.S., Larson, M.G., Leip, E.P., Evans, J.C., O’Donnell, C.J., Kannel, W.B., *et al.*, 2001. Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease. *New England Journal of Medicine*, **345**: 1291–1297.
- Vavalle, J.P., Lopes, R.D., Chen, A.Y., Newby, L.K., Wang, T.Y., Shah, B.R., *et al.*, 2012. Hospital Length of Stay in Patients with Non-ST-segment Elevation Myocardial Infarction. *The American Journal of Medicine*, **125**: 1085–1094.

- Wallentin, L., Becker, R.C., Budaj, A., Cannon, C.P., Emanuelsson, H., Held, C., *et al.*, 2009. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. *New England Journal of Medicine*, **361**: 1045–1057.
- Willerson, J.T., David Hillis, L., Winniford, M., and Maximilian Buja, L., 1986. Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes. *Journal of the American College of Cardiology*, **8**: 245–250.
- Willerson, J.T., Golino, P., Eidt, J., Campbell, W.B., and Buja, L.M., 1989. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. *Circulation*, **80**: 198–205.
- Yusuf, S., Zhao, F., Mehta, S.R., Chrolavicius, S., Tognoni, G., and Fox, K.K., 2001. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. *New England Journal of Medicine*, **345**: 494–502.
- Zannad, F., McMurray, J.J.V., Krum, H., van Veldhuisen, D.J., Swedberg, K., Shi, H., *et al.*, 2011. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. *New England Journal of Medicine*, **364**: 11–21.
- Zeller, M., Steg, P.G., Ravisy, J., Laurent, Y., Janin-Manificat, L., L’Huillier, I., *et al.*, 2005. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. *Archives of Internal Medicine*, **165**: 1192–1198.
- Zharov, E.I., Vertkin, A.L., Martynov, A.I., and Salnikov, S.N., 1991. Comparative evaluation of intravenous isosorbide dinitrate and nitroglycerin in patients with acute myocardial infarction. *Cardiology*, **79 Suppl 2**: 63–69.